Micronized Palmitoylethanolamide-Polydatin Reduces the Painful Symptomatology in Patients with Interstitial Cystitis/Bladder Pain Syndrome
Table 1
Demographic and baseline clinical characteristics of enrolled patients.
n
%
Age
51 ± 12.8
32
Sex
M
2
32
6
F
30
32
94
Menopause
16
29
55
BMI (kg/m2)
23.3 ± 5.2
23
Presence of major comorbidity
Systemic
16
32
Gynecologic
2
32
Previous urogynecological
7
32
Pain intensity (VAS score)
6.9 ± 2.4
ICSI score
11.0 ± 4.6
ICPI score
10.3 ± 3.8
PUF symptoms
12.6 ± 4.6
PUF bothers
11.0 ± 3.9
Bladder capacity (ml)
Cystomanometric
334.4 ± 116.4
24
On cystoscopy
655.2 ± 198.1
25
Voluntary micturition
180.20 ± 19.22
21
Cystoscopy
Glomerulations
24
26
92
Bleeding
23
26
88
Hunner lesions
11
25
44
Values are expressed as means ± standard deviation. Data are expressed as means ± SE; n = 32 at baseline and two months; 29 and 27 at four and six months, respectively. for pain intensity score reduction over time.
